Metraipolis › archive › dc_a12ebacd778e

Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer:… — Europe PMC PMID:42157161

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42157161
DOI
10.1186/s12885-[numero omesso]-y
License (as archived)
solo-consultazione
Archived
2026-11-01T13:42:59.987Z
SHA-256 of the archived text
34dc14ccc4f11cef1097a4612850c69ee04da27e9e252ac8c3a811019daca572
Stable URL of this page
https://metraipolis.com/documento/dc_a12ebacd778e

How to cite

Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer:… — Europe PMC PMID:42157161 — Europe PMC (en), https://europepmc.org/article/MED/42157161 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a12ebacd778e (Metraipolis archive dc_a12ebacd778e, sha256 34dc14ccc4f11cef1097a4612850c69ee04da27e9e252ac8c3a811019daca572)
BibTeX
@misc{dca12ebacd778e,
  title = {Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer:… — Europe PMC PMID:42157161},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42157161},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a12ebacd778e; sha256 34dc14ccc4f11cef1097a4612850c69ee04da27e9e252ac8c3a811019daca572},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42157161. Agents can read the archived copy with the MCP tool read_document.